Keyword: George Yancopoulos
Despite Regeneron's rhetoric, analysts are pessimistic about growth prospects for its I-O drug Libtayo and new trial data didn't calm their fears.
Dupixent has shown efficacy in multiple inflammations, but Regeneron CEO Len Schleifer wouldn't list COPD an indication it has "high confidence in."
Sanofi and Regeneron haven't seen the uptake they'd hoped for with Praluent, but now they've won a label expansion detailing the drug's CV benefits.
Regeneron CEO Len Schleifer netted $26.5 million in pay in 2018, keeping him among the top three highest-earning CEOs in the industry.
Regeneron's CEO calls Libtayo “the engine that could.” And Wednesday, those wondering, “could what?” got a glimpse at what the drug has done so far.
Regeneron's George Yancopoulos won a bonus of sorts in 2012, and now he's vested. This year, though, he and CEO Len Schliefer took a small cut.
The 2018 J.P. Morgan Healthcare Conference is receding in biopharma's rearview mirror, but industry watchers have only begun digesting the commentary.
Regeneron’s flagship med Eylea fell short of sales expectations in Q1, raising questions as Praluent idles and potential big-earner Dupixent makes its debut.
Regeneron CEO Len Schleifer has been at or near the top of the biopharma executive-pay charts for years. That’s still the case for 2016, but not by as wide a margin.
Allergan CEO Brent Saunders recently told investors that his company isn’t looking for any more “transformational” M&A. But on the chance a merger does put him out of a job? A mammoth goodbye present awaits.